Remember also that if Congress re-authorizes the "Priority Review Voucher Program",that CTIX becomes eligible for a Priority Review Voucher which could then be sold for 100's of millions of dollars due to Kevetrin's orphan designation for pediatric retinoblastoma application.
Kelt
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links